/content/dam/www/people-profile-photos/d/deborah-donnell/deborah-donnell-d.jpg
Donnell
Deborah Donnell, PhD
- Professor, Biostatistics, Bioinformatics and Epidemiology Program, Vaccine and Infectious Disease Division, Fred Hutch
- Professor, Biostatistics Program, Public Health Sciences Division, Fred Hutch
- Member, Translational Data Science Integrated Research Center (TDS IRC), Fred Hutch
- Adjunct Professor, Department of Global Health, University of Washington
Background
Dr. Deborah Donnell is a biostatistician with 25 years of experience in the design and analysis of clinical trials for HIV prevention. Her statistical leadership shapes pivotal trials in many areas of HIV prevention research and has included interventions to stop mother-to-child transmission; the treatment of opiate addiction; treatment as prevention in HIV-infected persons; and the use of pre-exposure prophylaxis, or PrEP — a once-a-day antiretroviral pill to prevent infection in those who are at high risk. She is the lead statistician for similar trials in the University of Washington Department of Global Heath, including numerous projects testing the most effective ways to expand use of PrEP in public health settings.
Education
University of Washington, 1987, PhD (Statistics)
University of Auckland, 1982, MA (Mathematics)
University of Auckland, 1980, BA (Mathematics and Music)
Current Projects
Principal Investigator of the Statistical and Data Management Center of the HIV Prevention Trials Network
Phase 2b trial of VRC01 as antibody meditated prevention of HIV in women in sub-Saharan Africa and men who have se with men in the Americas.
Phase 3 randomized double-dummy double-blind trial of Injectable Cabotegravir compared to FTC/TDF for the Prevention of HIV infection in Men who have sex with men and Transgender women.
ECHO, Multi-Center, Open-Label, Randomized Clinical Trial of the Effect of Progestin-Only Contraception versus the Copper Intrauterine Device (IUD) on the Risk of HIV Acquisition in Young Women
Design and delivery of combination HIV prevention in young South African women
Delivery of integrated PrEP and ART for HIV prevention for couples in Kenya
Impact of Concurrent Initiation of DMPA Contraception and Tenofovir PrEP on Bone Loss in Young Women
HIV self-testing and PrEP to increase testing and prevention uptake among male partners and improve postpartum ART use in PMTCT B+ programs in Uganda
Scalable, Effective Delivery of Microbicides and PrEP for Young Women in Kenya and South Africa
PrEP for young South African women: Evaluating uptake by risk screening or a decision support tool and scaled adherence support using a SMART design
HIV Self-Testing to Improve the Efficiency of PrEP Delivery
Broadly Neutralizing Antibody Study: Phase 1